Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
Payne Christopher D reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. director Christopher D. Payne reported two equity compensation awards in the form of Restricted Stock Units (RSUs) linked to Class A Common Stock. He received 8,223 RSUs that, subject to continuous service, will vest on the first quarterly vesting date after the earlier of the next annual stockholder meeting or the first anniversary of the grant date. He also received 545 RSUs issued under the Director Compensation Policy in lieu of a second-quarter 2026 cash retainer, calculated by dividing $16,598 of foregone fees by a $30.40 grant price; these RSUs will vest on the company’s next quarterly vesting date.
Perez Garcia Andrea G reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. director Andrea G Perez Garcia received a grant of 8,223 Restricted Stock Units (RSUs), each representing a contingent right to one share of Class A Common Stock. Subject to continuous service, the RSUs will vest in full on the first quarterly vesting date after the earlier of the next annual stockholder meeting or the first anniversary of the grant date. Following this award, reported direct holdings from this grant total 8,223 shares underlying RSUs.
Manuel Anja reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. director Manuel Anja received a grant of 8,223 Restricted Stock Units (RSUs) on August 12, 2026. Each RSU represents a contingent right to receive one share of Class A common stock. Subject to continuous service, all RSUs will vest on the first quarterly vesting date after the earlier of the next annual stockholder meeting or the first anniversary of the grant date, resulting in 8,223 shares held directly after the grant.
Cosgrove Delos M. reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. director Delos M. Cosgrove reported an award of 8,223 Restricted Stock Units (RSUs) relating to Class A Common Stock. The RSUs were granted at $0.00 per unit, bringing his reported direct holdings from this award to 8,223 RSUs.
Each RSU represents a contingent right to receive one share of Class A Common Stock. Subject to continuous service, the RSUs will vest in full on the first quarterly vesting date after the earlier of the company’s next annual stockholder meeting or the first anniversary of the grant date.
Autor Deborah M. reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. reported that Chief Policy Officer and director Deborah M. Autor received a grant of 8,223 Restricted Stock Units (RSUs) on 2026-08-12. Each RSU represents a contingent right to receive one share of Class A Common Stock, leaving her with 8,223 RSUs directly held after the award.
Subject to continuous service, these RSUs will vest in full on the first company quarterly vesting date following the earlier of the company’s next annual stockholder meeting or the first anniversary of the grant date.
Carroll Patrick Harrison reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. reported that Chief Medical Officer Patrick Harrison Carroll received a grant of 260 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The award was issued under the company’s Director Compensation Policy in lieu of a second-quarter 2026 director retainer fee of $7,912, based on a grant price of $30.40 per share. The RSUs will vest in full on the company’s next quarterly vesting date, after which the underlying shares may be delivered.
WELLS DAVID B reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. director David B. Wells reported two equity compensation awards in the form of Restricted Stock Units (RSUs). He received 8,223 RSUs, each representing one share of Class A common stock, which will vest in full on the first quarterly vesting date after the earlier of the next annual stockholder meeting or the first anniversary of the grant date, subject to continuous service. He also received 778 RSUs issued under the Director Compensation Policy in lieu of a $23,760 cash retainer for the second quarter of 2026, calculated at a grant price of $30.40 per share and vesting on the company’s next quarterly vesting date.
Amoo-Gottfried Kofi Owusu reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. reported that director Kofi Owusu Amoo-Gottfried received two equity compensation awards of Restricted Stock Units (RSUs) on August 12, 2026. One award covers 13,157 RSUs that, subject to continuous service, vest in three substantially equal installments over three years on company quarterly vesting dates. A second award covers 8,223 RSUs that, subject to continuous service, vest in full on the first quarterly vesting date after the earlier of the next annual stockholder meeting or the first anniversary of the grant date.
Hims & Hers Health, Inc. reported strong top-line growth but a sharp swing to losses for the quarter and six months ended June 30, 2026. Revenue rose to $753.2M in the quarter from $544.8M a year earlier, and to $1.36B for the first half from $1.13B, driven by expansion in the United States and rapid growth in international markets, including recent acquisitions.
Despite higher gross profit, the company recorded a net loss of $86.3M for the quarter and $178.4M year-to-date, compared with net income of $42.5M and $92.0M in the prior-year periods. The shift reflects substantially higher operating expenses, including marketing, general and administrative costs, amortization of newly acquired intangibles, and $38.1M in restructuring and related charges tied to changes in the U.S. weight-loss offering. The company also booked fair-value adjustments on contingent consideration and equity securities and accrued $62.5M for legal contingencies.
Total assets increased to $3.63B from $2.15B, mainly from the $968.5M Eucalyptus acquisition and the $153.0M YourBio acquisition, which together added significant goodwill and intangible assets. Liabilities rose to $3.30B, including $1.37B of convertible senior notes and large deferred and earn-out obligations, while stockholders’ equity declined to $324.1M. Operating cash flow remained positive at $53.4M for the first half, supported by working-capital movements and non-cash expenses, and cash and cash equivalents ended at $609.8M plus $231.2M of short-term investments.
Hims & Hers Health, Inc. reported strong top-line growth for the quarter ended June 30, 2026, with revenue of $753.2 million, up 38% year-over-year. Subscribers reached 2.9 million, a 19% increase, and monthly revenue per average subscriber rose 21% to $92, reflecting higher monetization per customer. International expansion was a major driver, as Rest of the World revenue grew more than 17-fold to $131.4 million, aided by the close of the Eucalyptus acquisition, while U.S. revenue grew 16%.
Profitability and cash metrics deteriorated. Gross margin declined from 76% to 64%, and the company swung from $42.5 million net income to a $86.3 million net loss in the quarter. Adjusted EBITDA fell from $82.2 million to $60.3 million, and quarterly Free Cash Flow remained negative at $(68.2) million. Operating expenses rose sharply, including higher marketing, operations, technology, and general and administrative costs, with notable legal contingencies and acquisition-related charges.
The balance sheet expanded significantly following acquisitions and new financing. Total assets increased to $3.63 billion, with goodwill and intangibles over $1.5 billion. Convertible senior notes grew to $1.37 billion, and total liabilities more than doubled to $3.30 billion, while stockholders’ equity declined to $324.1 million. Despite these pressures, cash and cash equivalents rose to $609.8 million, supported by note issuance. Management raised full-year 2026 guidance to $3.1–$3.3 billion in revenue and $275–$325 million Adjusted EBITDA, implying an Adjusted EBITDA margin of 9–10%, and guided third-quarter 2026 revenue to $880–$900 million with Adjusted EBITDA of $75–$95 million.